<DOC>
	<DOCNO>NCT00890656</DOCNO>
	<brief_summary>The goal clinical research study learn special combination chemotherapy drug call `` augmented hyper-CVAD chemotherapy '' give 6 8 month follow monthly maintenance chemotherapy one year help control acute lymphoblastic leukemia lymphoblastic lymphoma . The safety therapy also study .</brief_summary>
	<brief_title>Study Augmented Hyper-CVAD Acute Lymphoblastic Leukemia Salvage</brief_title>
	<detailed_description>The augmented hyper-CVAD chemotherapy combination chemotherapy drug include cyclophosphamide , vincristine , adriamycin , dexamethasone , pegaspargase give together one `` course '' treatment . It call `` augment '' additional drug add hyper-CVAD combination , standard combination chemotherapy drug treatment acute lymphoblastic leukemia lymphoblastic lymphoma . This switch back forth course chemotherapy drug methotrexate ara-C ( also vincristine , dexamethasone , pegaspargase ) . Before treatment start , physical exam , include blood ( 8 teaspoon ) test . You also bone marrow sample take ; sample take large needle hipbone . All participant receive 2 kind chemotherapy course total 8 course . Chemotherapy course give large vein central venous catheter ( plastic tube usually place collarbone ) . During treatment , physical exam give blood sample ( 1 tablespoon ) least twice week . A bone marrow sample repeat 2-3 week start treatment check response , later need . Course 1 include cyclophosphamide give vein 2-3 hour every 12 hour . This give 6 dos 3 day ( Days 1 , 2 3 ) . Adriamycin give vein 24 hour Day 4 . Vincristine give vein 15 30 minute Days 1 , 8 , 15 . Dexamethasone ( steroid ) give mouth vein Days 1 4 15-18 . Pegaspargase give vein 1-2 hour Day 1 . G-CSF ( growth colony stimulate factor ) give start 24 hour course chemotherapy finish ( Day 5 6 ) . It give help rapid recovery normal bone marrow . G-CSF inject vein skin blood count recover . Treatment brain give inside spinal fluid ( spinal tap ) ara-C methotrexate Days 2 7 Courses 1 2 total 4 treatment . This do decrease risk leukemia develop . During Course 2 , receive methotrexate infusion 24 hour first day ara-C vein high dose 2 hour every 12 hour 4 dos ( Days 2 3 ) . You also receive vincristine ( Days 1 , 8 , 15 ) , dexamethasone ( Days 1-4 15-18 ) , pegaspargase ( Day 5 ) . Citrovorum factor ( leucovorin ) , antidote side effect methotrexate , give vein mouth 2-3 day ( Day 2 ) . G-CSF give Course 1 ( 24 hour chemotherapy finish ) . The treatment brain inside spinal fluid give Course 1 Days 2 7 . The schedule chemotherapy switch hyper-CVAD ( Courses 3 , 5 , 7 ) methotrexate/ara-C ( Courses 4 , 6 8 ) complete total 8 course . After 8 course , go maintenance chemotherapy . This include daily 6-mercaptopurine take mouth , weekly methotrexate vein mouth , monthly vincristine vein , prednisone mouth 5 day every month . Maintenance therapy continue one year . Treatment give inpatient outpatient basis 8 intensive course chemotherapy , indicated condition . The maintenance treatment may give outpatient . Patients take study disease get bad intolerable side effect occur . This investigational study . All drug commercially available . Their use together study investigational . About 90 patient take part study . All enrol UT MD Anderson Cancer Center .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>Previously treat acute lymphoblastic leukemia ( ALL ) ( include Burkitt 's lymphoma ) lymphoblastic lymphoma relapse primary refractory ; No age restriction ; Zubrod performance status &lt; /= 3 ; Adequate liver ( bilirubin &lt; /= 3mg/dl unless consider due tumor ) renal function ( creatinine &lt; /= 3mg/dl unless consider due tumor ) ; Adequate cardiac function ( New York Heart Association ( NYHA ) &lt; III assess history physical examination )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Hyper-CVAD</keyword>
</DOC>